Should you have any questions, please contact Gerald Hsu, Ph.D., Senior Scientific Liaison, ( or
|
|
- Benjamin Washington
- 6 years ago
- Views:
Transcription
1 Montlukast Sodium Oral Granuls Typ of Posting Rvision Bulltin Posting Dat 29 Sp 2017 Official Dat 01 Oct 2017 Exprt Committ Chmical Mdicins Monographs 5 Rason for Rvision Complianc In accordanc with th Ruls and Procdurs of th Council of Exprts, th Chmical Mdicins Monographs 5 Exprt Committ has rvisd th Montlukast Sodium Oral Granuls Th purpos for th rvision is to: Rvis th accptanc critria of Sulfoxid from NMT 08% to NMT 10% and Total impuritis from NMT 10% to NMT 15% in th Organic Impuritis sction to match th spcification for an FDA approvd drug product Add Dis Tst 4 to accommodat a drug product which was approvd with diffrnt dis tst conditions and accptanc critria than th xisting dis tsts Th liquid chromatographic procdur usd for th analysis of th standard and sampl s in Dis Tst 4 is basd on analyss prformd with th ZORBAX Eclips XDB brand of L1 column manufacturd by Agilnt Th typical rtntion tim for montlukast is about 4 min Th Montlukast Sodium Oral Granuls Rvision Bulltin suprsds th currntly official monograph Th Rvision Bulltin will b incorporatd in th First Supplmnt to USP 41 NF 35 Should you hav any qustions, plas contact Grald Hsu, PhD, Snior Scintific Liaison, ( or gdh@usporg) C186436, C M4631-CHM52015, Rv
2 sulting Rvision Bulltin Official Octobr 1, 2017 Montlukast 1 through a suitabl filtr of 045-µm Montlukast Sodium Oral Granuls por siz or cntrifug to obtain a clar (S Chromatography 621, Systm Suitability) DEFINITION Montlukast Sodium Oral Granuls contain Montlukast So- Dtctor: UV 255 nm dium quivalnt to NLT 900% and NMT 1080% of th Columns labld amount of montlukast (C 35H 36ClNO 3S) Guard: 30-mm 4-mm; packing L11 [NOTE Avoid xposur of sampls containing montlukast Analytical: 46-mm 10-cm; 3-µm packing L11 to light] Column tmpratur: 50 IDENTIFICATION Flow rat: 15 ml/min A ULTRAVIOLET ABSORPTION 197U Injction volum: 20 µl Dilunt: Mthanol and watr (3:1) Run tim: 2 tims th rtntion tim of montlukast Standard : 33 µg/ml of USP Montlukast Di- cyclohxylamin RS in Dilunt Sampls: Standard,, Sampl stock : Nominally 002 mg/ml of and Snsitivity montlukast prpard as follows Transfr th contnts [NOTE Th rlativ rtntion tims for th cis-isomr of on packt to a suitabl volumtric flask, add 66% and montlukast ar about 092 and 10, of th flask volum of Dilunt, shak wll, and sonicat rspctivly] for 15 min with occasional shaking Cool to room tm- pratur, dilut with Dilunt to volum, and mix wll R: NLT 15 btwn th cis-isomr and Sampl : Nominally 2 µg/ml of montlukast montlukast, in Dilunt from th Sampl stock Pass a portion Rlativ standard dviation: NMT 20% for fiv in- of th rsulting through a suitabl filtr of jctions, Standard 045-µm por siz or cntrifug to obtain a clar Signal-to-nois ratio: NLT 10, Snsitivity Wavlngth rang: nm Accptanc critria: Th Sampl xhibits maxmontlukast (C 35H 36ClNO 3S) in th portion of Oral ima only at th sam wavlngths as th Standard Granuls takn: B Th rtntion tim of th major pak of th Sampl corrsponds to that of th Standard, as Rsult = (r U/r S) (C S/C U) (M r1/m r2) 100 obtaind in th Assay r U = pak rspons from th Sampl ASSAY r S = pak rspons from th Standard PROCEDURE C S = concntration of USP Montlukast Dilunt: Mthanol and watr (3:1) Solution A: 02% (v/v) trifluoroactic acid in watr Solution B: Mthanol and actonitril (3:2) C U = nominal concntration of montlukast in th Mobil phas: S Tabl 1 Sampl M r1 = molcular wight of montlukast, Tabl 1 M r2 = molcular wight of montlukast dicyclohxylamin, Tim Solution A Solution B Accptanc critria: 900% 1080% (min) (%) (%) PERFORMANCE TESTS Chang to rad: DISSOLUTION Tst Mdium: 05% (w/v) sodium dodcyl sulfat in watr; 900 ml Do not darat Standard : 033 mg/ml of USP Montlukast Tim: 15 min Dicyclohxylamin RS in Dilunt Solution A: 02% (v/v) trifluoroactic acid in watr : Transfr 10 ml of th Solution B: 02% (v/v) trifluoroactic acid in Standard to a clar 10-mL volumtric flask, add actonitril 4 µl of hydrogn proxid, and mix wll Expos th Mobil phas: Solution A and Solution B (1:1) flask for at last 4 h to ambint light or 10 min to a Standard stock : 033 mg/ml of USP 4 klx cool whit light [NOTE Montlukast is partially Montlukast Dicyclohxylamin RS in mthanol convrtd to th cis-isomr undr ths conditions] (quivalnt to 025 mg/ml of montlukast) Snsitivity : 033 µg/ml of USP Montlukast Standard : (L/900) mg/ml of montlukast in Dicyclohxylamin RS in Dilunt from th Standard Mdium from th Standard stock, whr L is th labl claim in mg/packt of montlukast Sampl : Nominally 024 mg/ml of Sampl : Plac th ntir contnts of on montlukast prpard as follows Transfr th quiva- packt in th baskt At th appropriat tim point, lnt of 60 mg of montlukast from th contnts of th pass a portion of th undr tst through a packts (NLT 15) to a 500-mL volumtric flask, and suitabl filtr to obtain a clar Discard th add 250 ml of Dilunt Shak wll and sonicat for 30 first 10 ml of th filtrat min, with occasional shaking Pass a portion of th r Th Unitd Stats Pharmacopial Convntion All Rights Rsrvd C186436, C M4631-CHM52015, Rv
3 2 Montlukast Official Octobr 1, 2017 (S Chromatography 621, Systm Suitability) Sampl: Standard Dtctor: UV 389 nm Rlativ standard dviation: NMT 20% Column: 30-mm 10-cm; 5-µm packing L11 Column tmpratur: 50 Flow rat: 09 ml/min Injction volum: 25 µl montlukast (C 35H 36ClNO 3S) dissolvd: Run tim: 15 tims th rtntion tim of montlukast Rsult = (r U/r S) C S V (1/L) 100 Sampl: Standard r U = pak rspons from th Sampl r S = pak rspons from th Standard Tailing factor: NMT 15 C S = concntration of montlukast in th Standard Rlativ standard dviation: NMT 20% V = volum of Mdium, 900 ml L = labl claim (mg/packt) Tolrancs: NLT 80% (Q) of th labld amount of montlukast (C 35H 36ClNO 3S) dissolvd: montlukast (C 35H 36ClNO 3S) is dissolvd Tst 3: If th product complis with this tst, th Rsult = (r U/r S) C S V (1/L) 100 labling indicats that it mts USP Dis Tst 3 Mdium: 05% (w/v) sodium dodcyl sulfat in r U = pak rspons of montlukast from th Sampl watr; 900 ml Apparatus 2: 50 rpm r S = pak rspons of montlukast from th Tim: 10 min Standard Solution A: 272 g/l of monobasic potassium phos- C S = concntration of montlukast in th Standard phat in watr Mobil phas: Actonitril and Solution A (70:30) V = volum of Mdium, 900 ml Dilunt: Actonitril and watr (50:50) L = labl claim (mg/packt) : Expos a portion of Stan- Tolrancs: NLT 85% (Q) of th labld amount of dard in a clar glass vial to dirct room light montlukast (C 35H 36ClNO 3S) is dissolvd for about 30 min Tst 2: If th product complis with this tst, th labl- Standard stock : 0524 mg/ml of USP ing indicats that it mts USP Dis Tst 2 Montlukast Dicyclohxylamin RS in Dilunt (quiva- Mdium: 05% (w/v) sodium dodcyl sulfat in lnt to 04 mg/ml of montlukast) watr; 900 ml Standard : mg/ml of USP Montlukast Dicyclohxylamin RS in Mdium from Tim: 15 min th Standard stock (quivalnt to 0005 mg/ Solution A: 007 g/l of monobasic sodium phosphat ml of montlukast) Solution B: Actonitril Sampl : Transfr th ntir contnts of on Mobil phas: Solution A and Solution B (45:55) Add packt to th dis vssl At th spcifid tim 133 ml/l of trithylamin and adjust with phos- point, withdraw 10 ml of sampl from th dis phoric acid to a ph of 67 vssl Pass a portion of th undr tst Standard stock : 01 mg/ml of montlukast through a suitabl filtr Discard th first 5 ml of th from montlukast sodium hydrat prpard as fol- filtrat lows Transfr a suitabl amount of montlukast so- dium hydrat to an appropriat volumtric flask Dis- (S Chromatography 621, Systm Suitability) solv in 4% of th flask volum of mthanol and dilut with Mdium to volum Dtrmin th watr Dtctor: UV 281 nm contnt of montlukast sodium hydrat at th tim of Column: 46-mm 3-cm; 3-µm packing L1 us Column tmpratur: 40 Standard : 0004 mg/ml of montlukast in Flow rat: 08 ml/min Mdium from th Standard stock Injction volum: 25 µl Sampl : Plac th ntir contnts of on Run tim: About 15 tims th rtntion tim of packt in th baskt At th appropriat tim point, montlukast cntrifug a portion of th undr tst Sampls: and Standard (S Chromatography 621, Systm Suitability) [NOTE Th rlativ rtntion tims for Z-isomr and Dtctor: UV 225 nm montlukast ar 08 and 10, rspctivly] Column: 46-mm 5-cm; 18-µm packing L1 Column tmpratur: 35 R: NLT 20 btwn th Z-isomr and Flow rat: 1 ml/min montlukast, Injction volum: 100 µl Tailing factor: NMT 20 for montlukast, Systm Run tim: 15 tims th rtntion tim of suitability montlukast Rlativ standard dviation: NMT 20%, Standard 2017 Th Unitd Stats Pharmacopial Convntion All Rights Rsrvd C186436, C M4631-CHM52015, Rv
4 Official Octobr 1, 2017 Montlukast 3 UNIFORMITY OF DOSAGE UNITS 905 Procdur for contnt uniformity Solution A, Solution B, Mobil phas, and Systm montlukast (C 35H 36ClNO 3S) dissolvd: suitability: Procd as dirctd in Dis Tst 1 Standard : 264 µg/ml of USP Montlukast Rsult = (r U/r S) C S V (1/L) (M r1/m r2) 100 Dicyclohxylamin RS in mthanol Sampl : Nominally 002 mg/ml of r U = pak rspons from th Sampl montlukast prpard as follows Transfr th contnts r S = pak rspons from th Standard of on packt to a suitabl volumtric flask, add 66% C S = concntration of USP Montlukast of th flask volum of mthanol, shak wll, and soni- cat for 15 min with occasional shaking Cool to room tmpratur, dilut with mthanol to volum, V = volum of Mdium, 900 ml and mix wll Pass a portion of th rsulting L = labl claim (mg/packt) through a suitabl filtr of 045-µm por siz or cn- M r1 = molcular wight of montlukast, trifug to obtain a clar M r2 = molcular wight of montlukast : Procd as dirctd in Disdicyclohxylamin, Tst 1, xcpt us an Injction volum of 5 µl Tolrancs: NLT 80% (Q) of th labld amount of montlukast (C 35H 36ClNO 3S) is dissolvd (RB 1-Oct-2016) Tst 4: If th product complis with this tst, th labling indicats that it mts USP Dis Tst 4 montlukast (C 35H 36ClNO 3S) in th packt takn: Mdium: 05% (w/v) sodium dodcyl sulfat in watr; 900 ml Rsult = (r U/r S) (C S/C U) (M r1/m r2) 100 Tim: 20 min r U = pak rspons from th Sampl Solution A: 39 g/l of sodium phosphat monobasic r S = pak rspons from th Standard dihydrat in watr Adjust with dilut phosphoric acid C S = concntration of USP Montlukast to a ph of 37 Mobil phas: Actonitril and Solution A (80:20) Dilunt: Mdium C U = nominal concntration of montlukast in th Standard : 0005 mg/ml of montlukast in Sampl Dilunt from montlukast sodium hydrat Dtrmin M r1 = molcular wight of montlukast, th watr contnt of montlukast sodium hydrat at M r2 = molcular wight of montlukast th tim of us dicyclohxylamin, Sampl : Plac th ntir contnts of on Accptanc critria: Mt th rquirmnts packt in th baskt At th spcifid tim point, withdraw 10 ml of sampl from th dis vssl IMPURITIES Pass a portion of th undr tst through a suitabl filtr papr Discard th first 3 ml of th filtrat Chang to rad: ORGANIC IMPURITIES (S Chromatography 621, Systm Suitability) Dilunt, Solution A, Solution B, Mobil phas, Stan- dard,, Snsitivity Dtctor: UV 254 nm, Sampl,, Column: 46-mm 15-cm; 5-µm packing L1 and : Procd as dirctd in th Tmpraturs Assay Autosamplr: 20 Column: 28 Flow rat: 15 ml/min Calculat th prcntag of any individual dgradation Injction volum: 50 µl product in th portion of Oral Granuls takn: Run tim: NLT 15 tims th rtntion tim of montlukast Rsult = (r U/r S) (C S/C U) (M r1/m r2) (1/F) 100 Sampl: Standard r U = pak rspons of any individual dgradation product from th Sampl Tailing factor: NMT 20 for montlukast r S = pak rspons of montlukast from th Rlativ standard dviation: NMT 20% Standard C S = concntration of USP Montlukast montlukast (C 35H 36ClNO 3S) dissolvd: C U = nominal concntration of montlukast in th Rsult = (r U/r S) C S V (1/L) 100 M r1 Sampl = molcular wight of montlukast, M r2 = molcular wight of montlukast r U = pak rspons from th Sampl dicyclohxylamin, r S = pak rspons from th Standard F = rlativ rspons factor (s Tabl 2) C S = concntration of montlukast in th Standard Accptanc critria: S Tabl 2 Disrgard any pak with an ara lss than that of th Snsitivity V = volum of Mdium, 900 ml L = labl claim (mg/packt) Tolrancs: NLT 80% (Q) of th labld amount of montlukast (C 35H 36ClNO 3S) is dissolvd (RB 1-Oct-2017) 2017 Th Unitd Stats Pharmacopial Convntion All Rights Rsrvd C186436, C M4631-CHM52015, Rv
5 4 Montlukast Official Octobr 1, 2017 Tabl 2 Rlativ Rlativ Accptanc Rtntion Rspons Critria, Nam Tim Factor NMT (%) 10 (RB 1-Oct- Sulfoxid b a, ) Montlukast kton c cis-isomr d Montlukast 10 Mthylkton f, 104 Michal adduct 1 g, 116 Michal adduct 2 h, 118 Mthylstyrn i, 155 Any othr individual dgradation product (RB 1-Oct- Total impuritis 2017) a Ths two impuritis ar not rsolvd by th mthod and nd to b intgratd togthr to dtrmin conformanc b [1-[[[1-[3-[(E)-2-(7-Chloroquinolin-2-yl)thnyl]phnyl]-3-[2-(1-hydroxy- 1-mthylthyl)phnyl]propyl]sulfinyl]mthyl]cyclopropyl]actic acid c (E)-1-{3-[2-(7-Chloroquinolin-2-yl)vinyl]phnyl}-3-[2-(2-hydroxypropan-2- yl)phnyl]propan-1-on d [1-[[[(1R)-1-[3-[(Z)-2-(7-Chloroquinolin-2-yl)thnyl]phnyl]-3-[2-(1-hydroxy-1-mthylthyl)phnyl]propyl]sulfanyl]mthyl]cyclopropyl]actic acid This is a procss and is includd in th tabl for idntification only This is controlld in th drug substanc It is not to b rportd for th drug product and should not b includd in th total impuritis f [1-[[[(1R)-3-(2-Actylphnyl)-1-[3-[(E)-2-(7-chloroquinolin-2- yl)thnyl]phnyl]propyl]sulfanyl]mthyl]cyclopropyl]actic acid g (1-{[(R)-1-(3-[(R)-1-{[1-(Carboxymthyl)cyclopropyl]mthylthio}-2-(7- chloroquinolin-2-yl)thyl]phnyl)-3-[2-(2-hydroxypropan-2-yl)phnyl- ]propylthio]mthyl}cyclopropyl)actic acid h (1-{[(R)-1-(3-[(S)-1-{[1-(Carboxymthyl)cyclopropyl]mthylthio}-2-(7- chloroquinolin-2-yl)thyl]phnyl)-3-[2-(2-hydroxypropan-2-yl)phnyl- ]propylthio]mthyl}cyclopropyl)actic acid i [1-[[[(1R)-1-[3-[(E)-2-(7-Chloroquinolin-2-yl)thnyl]phnyl]-3-[2-(1- mthylthnyl)phnyl]propyl]sulfanyl]mthyl]cyclopropyl]actic acid ADDITIONAL REQUIREMENTS PACKAGING AND STORAGE: Prsrv in tight containrs, protctd from light Stor at controlld room tmpratur LABELING: Whn mor than on Dis tst is givn, th labling stats th tst usd only if Tst 1 is not usd USP REFERENCE STANDARDS 11 USP Montlukast Dicyclohxylamin RS C 35H 36ClNO 3S C 12H 23N Th Unitd Stats Pharmacopial Convntion All Rights Rsrvd C186436, C M4631-CHM52015, Rv
Revision Bulletin 29 Dec Jan 2018 Non-Botanical Dietary Supplements Compliance
Niacin Extended-Release Tablets Type of Posting Posting Date Official Date Expert Committee Reason for Revision Revision Bulletin 29 Dec 2017 01 Jan 2018 Non-Botanical Dietary Supplements Compliance In
More informationRevision Bulletin 27 Jan Feb 2017 Non-Botanical Dietary Supplements Compliance
Niacin Extended-Release Tablets Type of Posting Posting Date Official Date Expert Committee Reason for Revision Revision Bulletin 27 Jan 2017 01 Feb 2017 Non-Botanical Dietary Supplements Compliance In
More informationAdditionally, minor editorial changes have been made to update the monograph to current USP style.
Extended-Release Tablets Type of Posting Revision Bulletin Posting Date 27 Oct 2017 Official Date 01 Nov 2017 Expert Committee Chemical Medicines Monographs 4 Reason for Revision Compliance In accordance
More informationThe Nitrofurantoin Capsules Revision Bulletin supersedes the currently official monograph.
Nitrofurantoin Capsules Type of Posting Revision Bulletin Posting Date 25 May 2018 Official Date 01 Jun 2018 Expert Committee Chemical Medicines Monographs 1 Reason for Revision Compliance In accordance
More informationDissolution Test 5 was validated using a Zodiac C18 brand of L1 column. The typical retention time for atorvastatin is about min.
Atorvastatin Calcium Tablets Type of Posting Posting Date 25 Jan 2019 Official Date 01 Feb 2019 Expert Committee Chemical Medicines Monographs 2 Reason for Revision Compliance In accordance with the Rules
More informationRevision Bulletin Official April 1, 2014 Alprazolam 1
. Apparatus Official April 1, 2014 Alprazolam 1 1: 100 rpm Alprazolam Extended-Release Tablets s: 1, 4, 8, and 12 h Mobile phase: Acetonitrile, tetrahydrofuran, and Medium (7:1:12) DEFINITION Alprazolam
More informationShould you have any questions, please contact Mary P. Koleck, Ph.D., Scientific Liaison ( or
Alfuzosin Hydrochloride Extended Release Tablets Type of Posting Posting Date 27 May 2016 Official Date 01 Jun 2016 Expert Committee Chemical Medicines Monographs 5 Reason for Revision Compliance In accordance
More informationUSP 36 Official Monographs / Metformin carding the first 3 ml of filtrate. Transfer 25 ml of the Analysis
. USP 36 Official Monographs / Metformin 4271 System suitability each of 5 s, at about 20,000 rpm, and allow to soak for Sample: System suitability solution 2 min. Repeat these steps two additional times.]
More informationDissolution Test 2 was validated using an Inertsil ODS-3V brand of L1 column. The typical retention time for donepezil is about 5.5 min.
Donepezil Hydrochloride Tablets Type of Posting Revision Bulletin Posting Date 27 Jan 2017 Official Date 01 Feb 2017 Expert Committee Chemical Medicines Monographs 4 Reason for Revision Compliance In accordance
More informationcontents of the currently official monograph. Please refer to the current edition of the USP NF for official text.
Metformin Hydrochloride Extended-Release Tablets Type of Posting Posting Date Targeted Official Date Notice of Intent to Revise 28 Sept 2018 To Be Determined, Revision Bulletin Expert Committee Chemical
More informationBRIEFING. (EXC: K. Moore.) RTS C Propylparaben C 10 H 12 O Benzoic acid, 4 hydroxy, propyl ester; Propyl p hydroxybenzoate [ ].
BRIEFING Propylparaben. The European Pharmacopoeia is the coordinating pharmacopeia for the international harmonization of the compendial standards for the Propylparaben monograph, as part of the process
More informationThe Isosorbide Mononitrate Extended-Release Tablets Revision Bulletin supersedes the currently official monograph.
Isosorbide Mononitrate Extended-Release Tablets Type of Posting Revision Bulletin Posting Date 5 Oct 2018 Official Date 8 Oct 2018 Expert Committee Chemical Medicines Monographs 2 Reason for Revision Compliance
More informationUSP 35 Official Monographs / Oxaliplatin 4143 DEFINITION
USP 35 Official Monographs / Oxaliplatin 4143 Assay preparation and the Standard preparation, respectively.. Where the test for Uniformity of dosage units has been performed using the Procedure for content
More informationcontents of the currently official monograph. Please refer to the current edition of the USP NF for official text.
Isosorbide Mononitrate Extended-Release Tablets Type of Posting Posting Date Targeted Official Date Notice of Intent to Revise 28 Sep 2018 To Be Determined, Revision Bulletin Expert Committee Chemical
More information7. Stability indicating analytical method development and validation of Ramipril and Amlodipine in capsule dosage form by HPLC.
7. Stability indicating analytical method development and validation of and in capsule dosage form by HPLC. 7.1 INSTRUMENTS AND MATERIALS USED 7.1.1 INSTRUMENTS 1. Shimadzu LC-2010 CHT with liquid chromatograph
More informationGive the letter that represents an atom (6) (b) Atoms of A and D combine to form a compound containing covalent bonds.
1 Th diagram shows th lctronic configurations of six diffrnt atoms. A B C D E F (a) You may us th Priodic Tabl on pag 2 to hlp you answr this qustion. Answr ach part by writing on of th lttrs A, B, C,
More informationARTEMETHER AND LUMEFANTRINE TABLETS: Final text for addition to The International Pharmacopoeia (July 2008)
July 2008 ARTEMETER AND LUMEFANTRINE TABLETS: Final text for addition to The International Pharmacopoeia (July 2008) This monograph was adopted at the Forty-second W Expert Committee on Specifications
More informationDETERMINATION OF DRUG RELEASE DURING DISSOLUTION OF NICORANDIL IN TABLET DOSAGE FORM BY USING REVERSE PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY
CHAPTER 9 DETERMINATION OF DRUG RELEASE DURING DISSOLUTION OF NICORANDIL IN TABLET DOSAGE FORM BY USING REVERSE PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY CHAPTER 9 Determination of drug release during
More informationARTEMETHER AND LUMEFANTRINE ORAL SUSPENSION:Final text for addition to The International Pharmacopoeia (November 2008)
November 2008 ` ARTEMETER AND LUMEFANTRINE RAL SUSPENSIN:Final text for addition to The International Pharmacopoeia (November 2008) Category. Antimalarial. Storage. Artemether and lumefantrine oral suspension
More informationANALYTICAL METHOD PROCEDURES
HPLC ASSAY AND RELATED SUBSTANCE Column Eurospher 100, C18, 25 x 0.40 cm 5µ Mobile Phase Buffer ph 2.0*: Acetonitrile (88:12 v/v) * Buffer ph 2 Potassium dihydrogen phosphate (KH 2 PO 4 ) - 0.68g Hepatane
More informationChapter 4: Verification of compendial methods
Chapter 4: Verification of compendial methods Introduction In order to ensure accurate and reliable test results, the quality control laboratory (QCL) needs to use analytical methods (and accompanying
More informationUSP 35 Official Monographs / Azithromycin 2279 C 38H 72N 2O 12 H 2O
. USP 35 Official Monographs / Azithromycin 2279 not more than 107.0 per cent of the labeled amount of azathioprine (C 9 H 7 N 7 O 2 S). Packaging and storage Preserve in Containers for Sterile Solids
More informationToward Self-Healing Hydrogels Using One-Pot. Thiol Ene Click and Borax-Diol Chemistry
Toward Slf-Haling Hydrogls Using On-Pot Thiol En Click and Borax-Diol Chmistry Lirong H 1, Danil Szopinski 1, Yang Wu 1, Grrit A. Luinstra 1, Patrick Thato* 1 1 Institut for Tchnical and Macromolcular
More information- A6/1 - APPENDIX 6. Identity, Physical and Chemical Properties, Details of Uses, Further Information, and Classification and Labelling
- A6/1 - APPENDIX 6 FORMAT FOR THE LISTING OF END POINTS TO BE INCLUDED IN THE REASONED STATEMENT OF THE OVERALL CONCLUSIONS DRAWN BY THE REGULATORY AUTHORITY (LEVEL 2) Chaptr 1: Proposd Idntity, Physical
More informationAssessment Schedule 2013 Chemistry: Demonstrate understanding of the properties of selected organic compounds (91165)
NCEA Lvl 2 Chmistry (91165) 2013 pag 1 of 5 Assssmnt Schdul 2013 Chmistry: Dmonstrat undrstanding of th proprtis of slctd organic compounds (91165) Assssmnt Critria Achivmnt Achivmnt with Mrit Achivmnt
More informationGas Chromatography Dr. Haibin Wan or Tel: (home) Gas Chromatography Columns
Dr. Haibin Wan mail: whbgby@cybrway.com.sg or hai-bin_wan@agilnt.com Tl: 6561662 (hom) ost widly usd instrumnt for organic analysis. Suitabl for volatil or smi volatil analyts. Not suitabl for non volatil
More informationChange to read: PROCEDURE Buffer: 3.9 g/l of ammonium acetate in water. Adjust
. Blank: Revision Bulletin Official June 1, 2013 Atorvastatin 1 Atorvastatin Calcium Diluent Samples: Sample solution and Blank Instrumental conditions (See Spectrophotometry and Light-Scattering 851.)
More informationNEVIRAPINE ORAL SUSPENSION Final text for addition to The International Pharmacopoeia (February 2009)
February 2009. NEVIRAPINE ORAL SUSPENSION Final text for addition to The International Pharmacopoeia (February 2009) This monograph was adopted at the Forty-third WHO Expert Committee on Specifications
More informationAnswer Homework 5 PHA5127 Fall 1999 Jeff Stark
Answr omwork 5 PA527 Fall 999 Jff Stark A patint is bing tratd with Drug X in a clinical stting. Upon admiion, an IV bolus dos of 000mg was givn which yildd an initial concntration of 5.56 µg/ml. A fw
More informationDetermination of Vibrational and Electronic Parameters From an Electronic Spectrum of I 2 and a Birge-Sponer Plot
5 J. Phys. Chm G Dtrmination of Vibrational and Elctronic Paramtrs From an Elctronic Spctrum of I 2 and a Birg-Sponr Plot 1 15 2 25 3 35 4 45 Dpartmnt of Chmistry, Gustavus Adolphus Collg. 8 Wst Collg
More informationEgualen Sodium Granules
Egualen Sodium Granules Dissolution Weigh accurately an amount of Egualen Sodium Granules, equivalent to about 5 mg of egualen sodium (C 15 H 17 NaO 3 S 1/3 H2O) according to the labeled amount,
More informationLearning Spherical Convolution for Fast Features from 360 Imagery
Larning Sphrical Convolution for Fast Faturs from 36 Imagry Anonymous Author(s) 3 4 5 6 7 8 9 3 4 5 6 7 8 9 3 4 5 6 7 8 9 3 3 3 33 34 35 In this fil w provid additional dtails to supplmnt th main papr
More informationChemical Physics II. More Stat. Thermo Kinetics Protein Folding...
Chmical Physics II Mor Stat. Thrmo Kintics Protin Folding... http://www.nmc.ctc.com/imags/projct/proj15thumb.jpg http://nuclarwaponarchiv.org/usa/tsts/ukgrabl2.jpg http://www.photolib.noaa.gov/corps/imags/big/corp1417.jpg
More informationCYCLOSERINE Final text for addition to The International Pharmacopoeia. (November 2008) CYCLOSERINUM CYCLOSERINE
December 2008 CYCLOSERINE Final text for addition to The International Pharmacopoeia (November 2008) This monograph was adopted at the Forty-third WHO Expert Committee on Specifications for Pharmaceutical
More informationBRIEFING. Pharmacopeial Discussion Group Sign Off Document Attributes EP JP USP Definition Loss on drying Readily carbonizable substances
BRIEFING Saccharin, NF 22 page 2825 and page 1711 of PF 29(5) [Sept. Oct. 2003]. The United States Pharmacopeia is the coordinating pharmacopeia for the international harmonization of the compendial standards
More informationOndansetron Hydrochloride Tablets
Ondansetron Hydrochloride Tablets Dissolution Perform the test with 1 tablet of Ondansetron Hydrochloride Tablets at 50 revolutions per minute according to the Paddle method, using 900 ml of water
More informationADVANTAME. Not less than 97.0% and not more than 102.0% on the anhydrous basis. Sweetener, flavour enhancer
ADVANTAME SYNONYMS INS No. 969 Prepared at the 80 th JECFA (2015), published in FAO JECFA Monographs 17 (2015), superseding tentative specifications prepared at 77 th JECFA (2013). An ADI of 0-5 mg/kg
More informationMolecules and Covalent Bond
Molculs and ovalnt ond Qustion Papr 1 Lvl IGSE Subjct hmistry (0620/0971) Exam oard ambridg Intrnational Examinations (IE) Topic toms, lmnts and compounds Sub-Topic Molculs and covalnt bonds ooklt Qustion
More informationChapter 6: Polarization and Crystal Optics
Chaptr 6: Polarization and Crystal Optics * P6-1. Cascadd Wav Rtardrs. Show that two cascadd quartr-wav rtardrs with paralll fast axs ar quivalnt to a half-wav rtardr. What is th rsult if th fast axs ar
More informationFirst derivative analysis
Robrto s Nots on Dirntial Calculus Chaptr 8: Graphical analysis Sction First drivativ analysis What you nd to know alrady: How to us drivativs to idntiy th critical valus o a unction and its trm points
More informationCh. 24 Molecular Reaction Dynamics 1. Collision Theory
Ch. 4 Molcular Raction Dynamics 1. Collision Thory Lctur 16. Diffusion-Controlld Raction 3. Th Matrial Balanc Equation 4. Transition Stat Thory: Th Eyring Equation 5. Transition Stat Thory: Thrmodynamic
More informationECE602 Exam 1 April 5, You must show ALL of your work for full credit.
ECE62 Exam April 5, 27 Nam: Solution Scor: / This xam is closd-book. You must show ALL of your work for full crdit. Plas rad th qustions carfully. Plas chck your answrs carfully. Calculators may NOT b
More informationLonicera japonica Flower Dry Extract. Proposed For Development Version 0.1. Published on Herbal Medicines Compendium (
Published on Herbal Medicines Compendium (https://hmc.usp.org) Lonicera japonica Flower Dry Extract Proposed For Development Version 0.1 Lonicera japonica Flower Dry Extract DEFINITION The article is prepared
More informationInternational Journal of Pharma Research and Health Sciences. Available online at
Volum (6), 4, Pag-57-5 CODEN (USA)-IJPRUR, -ISSN: 4-6465 Intrnational Journal of Pharma Rsarch and Halth Scincs Availabl onlin at www.pharmahalthscincs.nt Original Articl A Nw RP-HPLC Mthod for th Simultanous
More informationCase Study 1 PHA 5127 Fall 2006 Revised 9/19/06
Cas Study Qustion. A 3 yar old, 5 kg patint was brougt in for surgry and was givn a /kg iv bolus injction of a muscl rlaxant. T plasma concntrations wr masurd post injction and notd in t tabl blow: Tim
More information3.2.3 Molecules and Covalent Bonds
Sav My Exams! Th Hom of Rvision For mor awsom GSE and lvl rsourcs, visit us at www.savmyxams.co.uk/ 3.2.3 Molculs and ovalnt onds Qustion Papr Lvl IGSE Subjct hmistry (0620) Exam oard ambridg Intrnational
More informationEFAVIRENZ Final text for addition to The International Pharmacopoeia
Document QAS/05.145/FIAL March 07 EFAVIREZ Final text for addition to The International Pharmacopoeia This monograph was adopted at the Fortieth W Expert ommittee on Specifications for Pharmaceutical Preparations
More informationph People Grade Level: basic Duration: minutes Setting: classroom or field site
ph Popl Adaptd from: Whr Ar th Frogs? in Projct WET: Curriculum & Activity Guid. Bozman: Th Watrcours and th Council for Environmntal Education, 1995. ph Grad Lvl: basic Duration: 10 15 minuts Stting:
More informationLUMEFANTRINUM LUMEFANTRINE
July 2008 LUMEFANTRINE: Final text for addition to The International Pharmacopoeia (July 2008) This monograph was adopted at the Forty-second WHO Expert Committee on Specifications for Pharmaceutical Preparations
More informationTEMPLATE FOR AN EXAMPLE STANDARD TEST METHOD
APPENDIX V TEMPLATE FOR AN EXAMPLE STANDARD TEST METHOD Validating Chromatographic Methods. By David M. Bliesner Copyright 2006 John Wiley & Sons, Inc. 159 160 APPENDIX V Title: Effective: Document No:
More informationDehydrated Alcohol. » Dehydrated Alcohol contains not less than 99.2 percent, Pharmacopeial Forum Vol. 30(5) [Sept. Oct. 2004] HARMONIZATION 1847
Vol. 30(5) [Sept. Oct. 2004] HARMONIZATION 1847 The total of all other impurities in the chromatogram obtained with Test solution B: not more than the area of the peak due to 4-methylpentan-2-ol in the
More informationCIPAC. CIPAC Free relevant impurities methods:
CIPAC COLLABORATIVE INTERNATIONAL PESTICIDES ANALYTICAL COUNCIL LIMITED Commission Internationale des Méthodes d'analyse des Pesticides (CIMAP) CIPAC Free relevant impurities methods: Methods for relevant
More informationUnfired pressure vessels- Part 3: Design
Unfird prssur vssls- Part 3: Dsign Analysis prformd by: Analysis prformd by: Analysis vrsion: According to procdur: Calculation cas: Unfird prssur vssls EDMS Rfrnc: EF EN 13445-3 V1 Introduction: This
More informationPHA 5127 Answers Homework 2 Fall 2001
PH 5127 nswrs Homwork 2 Fall 2001 OK, bfor you rad th answrs, many of you spnt a lot of tim on this homwork. Plas, nxt tim if you hav qustions plas com talk/ask us. Thr is no nd to suffr (wll a littl suffring
More informationRadiation Physics Laboratory - Complementary Exercise Set MeBiom 2016/2017
Th following qustions ar to b answrd individually. Usful information such as tabls with dtctor charactristics and graphs with th proprtis of matrials ar availabl in th cours wb sit: http://www.lip.pt/~patricia/fisicadaradiacao.
More informationMEASURING HEAT FLUX FROM A COMPONENT ON A PCB
MEASURING HEAT FLUX FROM A COMPONENT ON A PCB INTRODUCTION Elctronic circuit boards consist of componnts which gnrats substantial amounts of hat during thir opration. A clar knowldg of th lvl of hat dissipation
More informationPrinciples of Humidity Dalton s law
Principls of Humidity Dalton s law Air is a mixtur of diffrnt gass. Th main gas componnts ar: Gas componnt volum [%] wight [%] Nitrogn N 2 78,03 75,47 Oxygn O 2 20,99 23,20 Argon Ar 0,93 1,28 Carbon dioxid
More informationDOXYCYCLINE HYCLATE Final text to replace published monograph in The International Pharmacopoeia (November 2007)
November 2007 DXYCYCLINE YCLATE Final text to replace published monograph in The International Pharmacopoeia (November 2007) This monograph was adopted at the Forty-first W Expert Committee on Specifications
More informationMethod Development and Validation Of Prasugrel Tablets By RP- HPLC
Method Development and Validation Of Prasugrel Tablets By RP- HPLC K.Sonia*, Ndwabe Hamunyare, K.Manikandan Department of Pharmaceutical Analysis, SRM College of Pharmacy, SRM University, Kattankulathur,
More informationMultiple Short Term Infusion Homework # 5 PHA 5127
Multipl Short rm Infusion Homwork # 5 PHA 527 A rug is aministr as a short trm infusion. h avrag pharmacokintic paramtrs for this rug ar: k 0.40 hr - V 28 L his rug follows a on-compartmnt boy mol. A 300
More informationLonicera japonica Flower Powder. Proposed For Development Version 0.1. Published on Herbal Medicines Compendium (
Published on Herbal Medicines Compendium (https://hmc.usp.org) Lonicera japonica Flower Powder Proposed For Development Version 0.1 Lonicera japonica Flower Powder DEFINITION The article consists of the
More informationAsian Journal of Research in Chemistry and Pharmaceutical Sciences Journal home page:
Research Article ISSN: 2349 7106 Asian Journal of Research in Chemistry and Pharmaceutical Sciences Journal home page: www.ajrcps.com ESTIMATION OF RAMELTEON IN TABLET DOSAGE FORM BY HPLC M. Jyothsna*
More informationSec 2.3 Modeling with First Order Equations
Sc.3 Modling with First Ordr Equations Mathmatical modls charactriz physical systms, oftn using diffrntial quations. Modl Construction: Translating physical situation into mathmatical trms. Clarly stat
More informationProblem Set #2 Due: Friday April 20, 2018 at 5 PM.
1 EE102B Spring 2018 Signal Procssing and Linar Systms II Goldsmith Problm St #2 Du: Friday April 20, 2018 at 5 PM. 1. Non-idal sampling and rcovry of idal sampls by discrt-tim filtring 30 pts) Considr
More informationSearch sequence databases 3 10/25/2016
Sarch squnc databass 3 10/25/2016 Etrm valu distribution Ø Suppos X is a random variabl with probability dnsity function p(, w sampl a larg numbr S of indpndnt valus of X from this distribution for an
More informationValidated RP-HPLC Method for Estimation of Cefprozil in Tablet Dosage Form
International Journal of PharmTech Research CDEN (USA): IJPRIF ISSN : 0974-4304 Vol.4, No.3, pp 1228-1232, July-Sept 2012 Validated RP-HPLC Method for Estimation of Cefprozil in Tablet Dosage Form Manzoor
More informationADVANTAME (TENTATIVE)
ADVANTAME (TENTATIVE) SYNONYMS INS No. 969 New tentative specifications prepared at the 77th JECFA (2013) and published in FAO JECFA Monographs 14 (2013). An ADI of 0-5 mg/kg body weight was established
More informationMCB137: Physical Biology of the Cell Spring 2017 Homework 6: Ligand binding and the MWC model of allostery (Due 3/23/17)
MCB37: Physical Biology of th Cll Spring 207 Homwork 6: Ligand binding and th MWC modl of allostry (Du 3/23/7) Hrnan G. Garcia March 2, 207 Simpl rprssion In class, w drivd a mathmatical modl of how simpl
More informationStatistical Thermodynamics: Sublimation of Solid Iodine
c:374-7-ivap-statmch.docx mar7 Statistical Thrmodynamics: Sublimation of Solid Iodin Chm 374 For March 3, 7 Prof. Patrik Callis Purpos:. To rviw basic fundamntals idas of Statistical Mchanics as applid
More information10. The Discrete-Time Fourier Transform (DTFT)
Th Discrt-Tim Fourir Transform (DTFT Dfinition of th discrt-tim Fourir transform Th Fourir rprsntation of signals plays an important rol in both continuous and discrt signal procssing In this sction w
More informationQuantitative Confirmatory Analysis of the NIDA 5 Panel Using Prelude SPLC System and TSQ Quantum Ultra MS
Quantitativ Confirmatory Analysis of th NIDA Panl Using Prlud SPLC Systm and TSQ Quantum Ultra MS Haiqiang (Bill) Yu, Kristin Van Natta, Marta Kozak Thrmo Fishr Scintific, San Jos, CA, USA Ovrviw Purpos:
More informationExtraction of Doping Density Distributions from C-V Curves
Extraction of Doping Dnsity Distributions from C-V Curvs Hartmut F.-W. Sadrozinski SCIPP, Univ. California Santa Cruz, Santa Cruz, CA 9564 USA 1. Connction btwn C, N, V Start with Poisson quation d V =
More informationKing Saud University College of Pharmacy Department of Pharmaceutics. Biopharmaceutics PHT 414. Laboratory Assignments 2010 G 1431 H
King Saud University College of Pharmacy Department of Pharmaceutics Biopharmaceutics PHT 414 Laboratory Assignments 20 G 1431 H Department of Pharmaceutics Biopharmaceutics PHT -414 Laboratory Assignments
More informationEFFECT OF CONSOLIDATION RATIOS ON MAXIMUM DYNAMIC SHEAR MODULUS OF SANDS
Octobr 12-17, 28, Bijing, China EFFECT OF CONSOLIDATION RATIOS ON MAXIMUM DYNAMIC SHEAR MODULUS OF SANDS Xiaoming YUAN 1 Jing SUN 2 and Rui SUN 3 1 Profssor, Dpt. of otchnical Enginring, Institut of Enginring
More informationPractical Pharmaceutical Technology I USP Dissolution Method for PARACETAMOL 500 mg Tablets Section No. 6 Group D
University of Jordan Faculty of Pharmacy Practical Pharmaceutical Technology I USP Dissolution Method for PARACETAMOL 500 mg Tablets Section No. 6 Group D USP Dissolution Method for PARACETAMOL 500 mg
More informationErrata. Items with asterisks will still be in the Second Printing
Errata Itms with astrisks will still b in th Scond Printing Author wbsit URL: http://chs.unl.du/edpsych/rjsit/hom. P7. Th squar root of rfrrd to σ E (i.., σ E is rfrrd to not Th squar root of σ E (i..,
More informationA=P=E M-A=N Alpha particle Beta Particle. Periodic table
Nam Pr. Atomic Structur/Nuclar Chmistry (Ch. 3 & 21) OTHS Acadmic Chmistry Objctivs: Undrstand th xprimntal dsign and conclusions usd in th dvlopmnt of modrn atomic thory, including Dalton's Postulats,
More informationFast methods for the determination of ibuprofen in drug products
APPLICATION NOTE 779 Fast s for the determination of ibuprofen in drug products Authors Sylvia Grosse, Mauro De Pra, Frank Steiner, Thermo Fisher Scientific, Germering, Germany Keywords Pharmaceutical,
More informationCoupled Pendulums. Two normal modes.
Tim Dpndnt Two Stat Problm Coupld Pndulums Wak spring Two normal mods. No friction. No air rsistanc. Prfct Spring Start Swinging Som tim latr - swings with full amplitud. stationary M +n L M +m Elctron
More informationLaboratory work # 8 (14) EXPERIMENTAL ESTIMATION OF CRITICAL STRESSES IN STRINGER UNDER COMPRESSION
Laboratory wor # 8 (14) XPRIMNTAL STIMATION OF CRITICAL STRSSS IN STRINGR UNDR COMPRSSION At action of comprssing ffort on a bar (column, rod, and stringr) two inds of loss of stability ar possibl: 1)
More informationElectrochemistry L E O
Rmmbr from CHM151 A rdox raction in on in which lctrons ar transfrrd lctrochmistry L O Rduction os lctrons xidation G R ain lctrons duction W can dtrmin which lmnt is oxidizd or rducd by assigning oxidation
More informationOutline. Thanks to Ian Blockland and Randy Sobie for these slides Lifetimes of Decaying Particles Scattering Cross Sections Fermi s Golden Rule
Outlin Thanks to Ian Blockland and andy obi for ths slids Liftims of Dcaying Particls cattring Cross ctions Frmi s Goldn ul Physics 424 Lctur 12 Pag 1 Obsrvabls want to rlat xprimntal masurmnts to thortical
More informationHuman vision is determined based on information theory:
Human vision is dtrmind basd on information thory: Supplmntary Information Alfonso Dlgado-Bonal,2 and F. Javir Martn Torrs,3 [] Instituto Andaluz d Cincias d la Tirra CSIC-UGR, Avda. d Las Palmras n 4,
More informationUltimate strength analysis & design of residential slabs on reactive soil
Ultimat strngth analysis & dsign of rsidntial slabs on ractiv soil This documnt prsnts an ovrviw of thory undrlying ultimat strngth analysis and dsign of stiffnd raft and waffl raft slabs, as commonly
More informationWhat are those βs anyway? Understanding Design Matrix & Odds ratios
Ral paramtr stimat WILD 750 - Wildlif Population Analysis of 6 What ar thos βs anyway? Undrsting Dsign Matrix & Odds ratios Rfrncs Hosmr D.W.. Lmshow. 000. Applid logistic rgrssion. John Wily & ons Inc.
More informationPhosphonate-Functionalized Polystyrene Microspheres with Controlled Zeta Potential for Efficient Uranium Sorption
Elctronic Supplmntary Matrial (ESI) for RSC Advancs. This journal is Th Royal Socity of Chmistry 2016 Supporting Information Phosphonat-Functionalizd Polystyrn Microsphrs with Controlld Zta Potntial for
More informationSara Godoy del Olmo Calculation of contaminated soil volumes : Geostatistics applied to a hydrocarbons spill Lac Megantic Case
wwwnvisol-canadaca Sara Godoy dl Olmo Calculation of contaminatd soil volums : Gostatistics applid to a hydrocarbons spill Lac Mgantic Cas Gostatistics: study of a PH contamination CONTEXT OF THE STUDY
More informationANALYSIS IN THE FREQUENCY DOMAIN
ANALYSIS IN THE FREQUENCY DOMAIN SPECTRAL DENSITY Dfinition Th spctral dnsit of a S.S.P. t also calld th spctrum of t is dfind as: + { γ }. jτ γ τ F τ τ In othr words, of th covarianc function. is dfind
More information2008 AP Calculus BC Multiple Choice Exam
008 AP Multipl Choic Eam Nam 008 AP Calculus BC Multipl Choic Eam Sction No Calculator Activ AP Calculus 008 BC Multipl Choic. At tim t 0, a particl moving in th -plan is th acclration vctor of th particl
More informationPYRIPROXYFEN TECHNICAL
WHO/IS/TC/715/2001 TECHNICAL TECHNICAL 1. Specification 1.1 Description Interim specification WHO/IS/TC/715/2001 The material shall consist of pyriproxyfen together with related manufacturing impurities.
More informationSerge 10% COLLECTION REFLECTS SUNLIGHT OUTDOORS GLASSFIBRE OF = 10%
Srg 10% COLLECTION 2018-2021 REFLECTS SUNLIGHT OUTDOORS GLASSFIBRE OF = 10% Scrns that rflct & absorb solar nrgy outsid th hous. Mt OUT. Srg 10% GLASSFIBRE OF = 10% Tchnical spcifications Srg 600 010010
More informationTEMASEK JUNIOR COLLEGE, SINGAPORE. JC 2 Preliminary Examination 2017
TEMASEK JUNIOR COLLEGE, SINGAPORE JC Prliminary Eamination 7 MATHEMATICS 886/ Highr 9 August 7 Additional Matrials: Answr papr hours List of Formula (MF6) READ THESE INSTRUCTIONS FIRST Writ your Civics
More information15. Stress-Strain behavior of soils
15. Strss-Strain bhavior of soils Sand bhavior Usually shard undr draind conditions (rlativly high prmability mans xcss por prssurs ar not gnratd). Paramtrs govrning sand bhaviour is: Rlativ dnsity Effctiv
More informationEcrano COLLECTION REFLECTS SUNLIGHT OUTDOORS GLASSFIBRE OF = 2%
Ecrano COLLECTION 2018-2021 REFLECTS SUNLIGHT OUTDOORS GLASSFIBRE OF = 2% Scrns that rflct & absorb solar nrgy outsid th hous. Mt OUT. Ecrano GLASSFIBRE OF = 2% Tchnical spcifications Ecrano 002010 whit
More informationByeong-Joo Lee
OSECH - MSE calphad@postch.ac.kr Equipartition horm h avrag nrgy o a particl pr indpndnt componnt o motion is ε ε ' ε '' ε ''' U ln Z Z ε < ε > U ln Z β ( ε ' ε '' ε ''' / Z' Z translational kintic nrgy
More informationCHAPTER - 3 ANALYTICAL PROFILE. 3.1 Estimation of Drug in Pharmaceutical Formulation Estimation of Drugs
CHAPTER - 3 ANALYTICAL PROFILE 3.1 Estimation of Drug in Pharmaceutical Formulation 3.1.1 Estimation of Drugs ANALYTICAL PROFILE 84 3.1 ESTIMATION OF DRUG IN PHARMACEUTICAL FORMULATION. Agrawal A et al
More informationHigher order derivatives
Robrto s Nots on Diffrntial Calculus Chaptr 4: Basic diffrntiation ruls Sction 7 Highr ordr drivativs What you nd to know alrady: Basic diffrntiation ruls. What you can larn hr: How to rpat th procss of
More informationTitle: Vibrational structure of electronic transition
Titl: Vibrational structur of lctronic transition Pag- Th band spctrum sn in th Ultra-Violt (UV) and visibl (VIS) rgions of th lctromagntic spctrum can not intrprtd as vibrational and rotational spctrum
More informationRobust surface-consistent residual statics and phase correction part 2
Robust surfac-consistnt rsidual statics and phas corrction part 2 Ptr Cary*, Nirupama Nagarajappa Arcis Sismic Solutions, A TGS Company, Calgary, Albrta, Canada. Summary In land AVO procssing, nar-surfac
More informationProperties and types of water. Properties of water
PART 3 Proprtis and typs of watr Proprtis of watr Chmical form: H 2 O Physical stats: gas (vapor) liquid (watr) solid (ic, snow) Molcular structur: On oxygn atom and two hydrogn atoms ar arrangd as in
More information